TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: time to first response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetic equivalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal changes in SBP, DBP, and PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in plasma LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in plasma HDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum level of progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum level of DHEAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum level of estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Target vessel revascularization (TVR)
Endpoint domain: Adverse events/effects
Primary endpoint: Major adverse events (including death, myocardial infarction, and stent thrombosis)
Endpoint domain: Adverse events/effects
Primary endpoint: Bone mineral density (BMD) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pulsatility index in the middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Responder rates at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom score of TCM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lecithin body number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hair growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hair loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug-related sexual adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Alterations in IBS-associated microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic stroke events
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of late foreign-body cell reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of lens epithelial cell (LEC) outgrowth
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of posterior capsule opacification (PCO)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in wrinkle measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight regain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic venous thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Sunscreen use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: traction force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regurgitation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: vomiting of feeding substrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: glucose profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cough severity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vo2 peak indexed to fat-free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Indexed cardiac output during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reductions in illness intrusiveness
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Vaccine efficacy against hospital-diagnosed pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Functional scores (Constant score, SST, ASES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peripheral fat loss of > or = 2 kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of exit site infection (ESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of peritonitis
Endpoint domain: Adverse events/effects
Primary endpoint: parasympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: balance of autonomic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat-protein content ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Drug safety
Endpoint domain: Adverse events/effects
Primary endpoint: percentage difference in the number of stent cross-sections with a thrombotic area >5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall cure rate
Endpoint domain: Mortality/survival
Primary endpoint: Pain experienced during hysteroscopy and endometrial biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vaso-vagal reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Venous glycyl-glutamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pulse Rate change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TIMI-risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite endpoint rate at 30 days and 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Self-assessed CPR confidence scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Willingness to perform bystander CPR
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: levels of phosphorylated EGFR (pEGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enhanced apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: burning sensation
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction in appropriate but unnecessary therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of ATP in terminating FVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apoptosis induction in gastric cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferative potency inhibition in gastric cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraceptive uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Median percentage reduction of baseline lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of intraoperative dreams
Endpoint domain: Adverse events/effects
Primary endpoint: Antiproliferative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Granulation tissue growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean treatment cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: FHSQ shoe fit improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FHSQ general health improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FHSQ foot pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprocedure bloating assessed 24-48 hours after the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: improved or normalized classroom functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved academic functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: require renal replacement therapy
Endpoint domain: Adverse events/effects
Primary endpoint: die in hospital
Endpoint domain: Mortality/survival
Primary endpoint: Increased confidence identifying melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: femoral neck BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total hip BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ghrelin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: (13)C-glucose appearance in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean IOP change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Plasma concentration of PGE2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synovial fluid concentration of PGE2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TxB2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum power generated during ergometry tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6-month postoperative CDVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dehydration prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total water intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total serum bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deaths from coronary heart disease or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Primary cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma ascorbic acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of TCZ responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RV end-systolic volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: death or recurrent MI
Endpoint domain: Mortality/survival
Primary endpoint: Serum acetate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum butyrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intensity of pricking pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of 3D-PEM for small lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of WBPET for small lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of 3D-PEM and WBPET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-induced dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BPI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy to refrain from smoking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptance of cravings to smoke
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urinary Glucose Excretion (UGE) on day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure for recreational sports activities (EE(RECSPORT))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure for leisure-time physical activity (EE(LTPA))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance-based fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak torque during extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: bother from asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caregiver quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of contralateral breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of ipsilateral breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total inspiratory work (Wi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pain score with movement at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful transition to oral selexipag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient convenience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median consultation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates with postal screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: FA concentrations in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in MRSA acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: baseline impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain increase at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Square allodynic area increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF interleukin‐8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Length of Stay Sensitive to Nutritional Support (LOSNDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NMP absorption and elimination half-lives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in clinician-rated SAD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GFL, HFL, LPL improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of recurrent embolic events
Endpoint domain: Mortality/survival
Primary endpoint: Nonfatal stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Bioavailability of melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy and safety of intracoronary abciximab bolus administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis confirmation of choroidal melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of extrascleral extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of iron deficiency anemia (IDA) at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of iron deficiency (ID) at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of iron deficiency (ID) at 6 months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Daily systemic exposure of dapsone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profiles of dapsone formulations
Endpoint domain: Adverse events/effects
Primary endpoint: CV safety of empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective and objective measures of sleepiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slower choice reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first postoperative anal exhaust
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean nerve density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: total nerve number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: main nerve trunks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: long-term effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to voiding after spinal injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to hospital discharge after spinal injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nifedipine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking distance on the day of discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxytocin augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrapartum adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Mean UDVA 10 minutes postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of adequate inspection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMP PC(20) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prechallenge forced expiratory flow at 25% to 75% of maximal lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in observer-assessed POSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in patient-assessed POSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global Aesthetic Improvement Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median resolution times of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Service need
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: all stroke or death rate at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: in-stent restenosis rate at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: periprocedural complication rate at 24 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients achieving LDL-C target values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak DSVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean DSVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic availability of FP (area under the plasma FP concentration‐time curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reflective/cognitive impulsivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of fetuin-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of MGP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of liver injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical resolution at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriological response rates at the end of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological success at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with study recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ease of insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depth of sigmoidoscope insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Major heart events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of target attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to activities around normalizing eating, weight gain, and education about anorexia nervosa
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: symptom change following treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximal voluntary contraction pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean POBF increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of BPH symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes